Immunomodulatory properties of MAPCs and uses thereof

A method of ameliorating an immune dysfunction in a subject, comprising:

• administering to the subject multipotent adult progenitor cells characterized in that they are not embryonic stem cells, not embryonic germ cells, and not germ cells, express telomerase, have a normal karyotype, are not tumorigenic and are allogeneic to the subject;
• wherein the cells are administered adjunctively to one or more other treatments, wherein the cells have not been genetically engineered to improve their immunological properties, and wherein the immune dysfunction is not GVHD and is not diabetes.

A method of ameliorating an immune dysfunction in a subject, comprising:

• administering to the subject multipotent adult progenitor cells characterized in that they are not embryonic stem cells, not embryonic germ cells, and not germ cells, are positive for oct3/4, have a normal karyotype, are not tumorigenic and are allogeneic to the subject;
• wherein the cells are administered adjunctively to one or more other treatments, wherein the cells have not been genetically engineered to improve their immunological properties, and wherein the immune dysfunction is not GVHD and is not diabetes.

A method of ameliorating an immune dysfunction in a subject, comprising:

• administering to the subject multipotent adult progenitor cells characterized in that they are not embryonic stem cells, not embryonic germ cells, and not germ cells, have undergone at least 40 cell doublings in culture, have a normal karyotype, are not tumorigenic and are allogeneic to the subject;
• wherein the cells are administered adjunctively to one or more other treatments, wherein the cells have not been genetically engineered to improve their immunological properties, and wherein the immune dysfunction is not GVHD and is not diabetes.